PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 2 55-2, 2004, Pages

  Bagi, Zsolt ^a   Koller, Akos ^a   Kaley, Gabor ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Catalase; Endothelium; NAD(P)H oxidase; Rosiglitazone; Superoxide

Indexed keywords

8 ISOPROSTANE; APOCYNIN; GLUCOSE; ISOPROSTANE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSIGLITAZONE; SUPEROXIDE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCHOLINE; ADENOSINE; ANTIDIABETIC AGENT; CELL RECEPTOR; NITRIC OXIDE DONOR; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERIOLE; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG MECHANISM; ENZYME ACTIVITY; GENE ACTIVATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ACETYLCHOLINE; ADENOSINE; ANIMALS; ARTERIOLES; BIOLOGICAL AVAILABILITY; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; OXIDATIVE STRESS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VASODILATION;

EID: 0942276496     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00718.2003     Document Type: Article

References (30)

1. Akkus I, Kalak S, Vural H, Caglayan O, Menekse E, Can G, and Durmus B. Leukocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase and serum and leukocyte vitamin C levels of patients with type II diabetes mellitus. Clin Chim Acta 244: 221-227, 1996.
2. Bagi Z, Koller A, and Kaley G. Superoxide-NO interaction decreases flow- and agonist-induced dilation of isolated coronary arterioles of mice with Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 285: H1404-H1410, 2003.
3. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
4. Belke DD, Larsen TS, and Severson DL. Cardiac function in perfused hearts from diabetic mice. Adv Exp Med Biol 498: 241-245, 2001.
5. Caballero A, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, LoGerfo FW, Horton ES, and Veves A. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52: 173-180, 2003.
6. Calnek DS, ML, Roser S, Roman J, and Hart CM. Peroxisome proliferator-activated receptor-γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23: 52-57, 2003.
7. Chatham JC, Forder JR, and McNeill JH. The Heart in Diabetes. Norwell, MA: Kluwer Academic, 1996, p. 1-267.
8. De Vriese AS, Verbeuren TJ, Van De Voorde J, Lameire NH, and Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 130: 963-974, 2000.
9. Frisbee JC, Maier KG, and Stepp DW. Oxidant stress-induced increase in myogenic activation of skeletal muscle resistance arteries in obese Zucker rats. Am J Physiol Heart Circ Physiol 283: H2160-H2168, 2002.
10. Fujishima S, Ohya Y, Nakamura Y, Onaka U, Abe I, and Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens 11: 1134-1137, 1998.
11. Fujiwara T, Ohsawa T, Takahashi S, Ikeda K, Okuno A, Ushiyama S, Matsuda K, and Horikoshi H. Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats. Life Sci 63: 2039-2047, 1998.
12. Girnun GD, Domann FE, Moore SA, and Robbins MEC. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 16: 2793-2801, 2002.
13. Giugliano D, Ceriello A, and Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267, 1996.
14. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, and Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656-1662, 2002.
15. Hummel KP, Dickie MM, and Coleman DL. Diabetes, a new mutation in the mouse. Science 153: 1127-1128, 1966.
16. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50: 3-11, 2001.
17. Inoue I, Shino K, Noji S, Awata T, and Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPARα) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246: 370-374, 1998.
18. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, and Hsueh WA. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318, 2000.
19. Mahgoub MA and Abd-Elfattah AS. Diabetes mellitus and cardiac function. Mol Cell Biochem 180: 59-64, 1998.
20. Martens FM, Visseren FL, Lemay J, de Koning EJ, and Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62: 1463-1480, 2002.
21. Mezzetti A, Cipollone F, and Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res 47: 475-488, 2000.
22. Mohazzab KM, Kaminski PM, and Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol Heart Circ Physiol 266: H2568-H2572, 1994.
23. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827, 2001.
24. Picard F and Auwerx J. PPAR(γ) and glucose homeostasis. Annu Rev Nutr 22: 167-197, 2002.
25. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, Giaid A, and Harrison DG. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 30: 29-34, 1997.
26. Shehadeh A and Regan TJ. Cardiac consequences of diabetes mellitus. Clin Cardiol 18: 301-305, 1995.
27. Stakos DA, SD, Sparks EA, Wooley CF, Osei K, and Boudoulas H. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study. J Cardiol 41: 183-190, 2003.
28. Stehouwer CD, Lambert J, Donker AJ, and van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34: 55-68, 1997.
29. Turner RC, Milins H, Neil HA, Stratton IM, Manley SE, Matthews DR, and Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316: 823-828, 1998.
30. Walker AB, Chattington PD, Buckingham RE, and Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48: 1448-1453, 1999.